Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | PDE6D | O43924 | 1/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4600403 | 0.88 | HMGCR (0.59) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL10297392 | 0.86 | HMGCR (0.68) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL4601260 | 0.83 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL10297393 | 0.82 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL13928073 | 0.81 | HMGCR (0.65) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL4601462 | 0.79 | HMGCR (0.52) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL12573729 | 0.78 | HMGCR (0.66) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL12573851 | 0.77 | HMGCR (0.52) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL2301657 | 0.76 | HMGCR (0.53) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL12130486 | 0.76 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8212035-B2 | Process for preparation of rosuvastatin calcium field of the invention | AUROBINDO PHARMA LTD. (IN) | 2012-07-03 | — | — | US | disclosed |
| US-20090312547-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM FIELD OF THE INVENTION | AUROBINDO PHARMA LTD (IN) | 2009-12-17 | — | — | US | disclosed |
| EP-2125754-A1 | AN IMPROVED PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM | Aurobindo Pharma Limited (IN) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008096257-A1 | AN IMPROVED PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM | AUROBINDO PHARMA LIMITED (IN) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312547-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM FIELD OF THE INVENTION | CACNA1C, CACNG5, CACNA1A | HMGCR 18/4885ALDH1A1 2101/4885CYP3A4 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.